About this trial
To explore the relationship between perioperative blood pressure and catecholamine concentrations in adrenal venous blood and peripheral venous blood in hypertensive patients with primary aldosteronism (PA) who underwent percutaneous selective adrenal artery embolization (SAAE). In order to elucidate the related phenomena and possible mechanisms of blood pressure fluctuations caused by SAAE treatment in hypertensive patients with PA.
Eligibility criteria
Qualifiers
Age ≥18 years with no gender restrictions.
Adherence to the "Primary Aldosteronism" Diagnosis and Treatment Guidelines, confirmed diagnosis of primary aldosteronism following rigorous drug washout, and identification as either aldosteronoma or idiopathic aldosteronism via adrenal vein blood sampling.
Blood pressure metrics that satisfy any of the subsequent conditions: a) Clinic-recorded blood pressure ≥140/90mmHg; b) 24-hour ambulatory blood pressure monitoring results displaying average blood pressure >130/80 mmHg or daytime readings >135/85 mmHg.
Adrenal CT scan revealing adrenal hyperplasia, nodular formations, or no significant morphological deviations.
Disqualifiers
Patients diagnosed with primary hypertension or secondary hypertension attributed to other etiologies.
Female participants who are presently pregnant, lactating, or with intentions to conceive within the forthcoming year.
Presence of significant systemic diseases, with particular attention to hepatic and renal dysfunction.
Pronounced allergic reaction to contrast agents.
Trial design
Treatments tested in this trial
- Selective adrenal artery embolization